Evaluating the effects of radiotherapy on patients with oligometastatic cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the impact of Stereotactic ABlative Radiotherapy (SABR) on patients with oligometastatic cancer, which is characterized by a limited number of metastases. By collecting clinical data, medical images, and biological samples from multiple centers, the study seeks to identify patient profiles that respond favorably to SABR. The research will utilize artificial intelligence to analyze this data and predict which patients are most likely to benefit from the treatment, ultimately aiming to improve survival rates and quality of life for these patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologic confirmation of primary tumor: breast, prostate, lung, colorectal.
* 18 years old or older.
* Up to five metastases located in the bone, lung, node, liver or brain.
* Eastern Cooperative Oncology Group (ECOG) Performance Status Scale 0 or 1.

Exclusion Criteria:

* Non-melanoma skin cancer.
* Previous radiotherapy in the same anatomic location.
* Presence of vascular collagen disease.
* Pregnancy or lactation at the time of inclusion.

Where it's running

• Hospital Universitari Sant Joan de Reus
  Reus, Tarragona, Spain Recruiting
• Complejo Hospitalario Universitario Albacete
  Albacete, Albacete, Spain Not yet recruiting
• Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
  Barcelona, Barcelona, Spain Not yet recruiting
• Hospital Universitari Vall d'Hebron
  Barcelona, Barcelona, Spain Not yet recruiting
• Institut Català d'Oncologia
  Barcelona, Barcelona, Spain Not yet recruiting
• Hospital Universitario Virgen de las Nieves
  Granada, Granada, Spain Not yet recruiting

Study contacts

• Study coordinator: Jorge Joven, Prof.
• Email: jorge.joven@urv.cat
• Phone: +34977310300

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating BBO-10203 for advanced solid tumors

  This study is testing a new treatment called BBO-10203, alone and with another drug, to see if it can help people with advanced solid tumors, including certain types of breast cancer.

  Recruiting at 43 sites Phase 1 TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · Duarte, California and 43 other locations · NCT06625775

• Radiation treatment for high-risk spine cancer patients

  This study is testing a new type of radiation treatment for patients with cancer that has spread to the spine to see if it can help manage their condition without needing major surgery.

  Recruiting Phase 2 Stony Brook University · Stony Brook, New York · NCT06165419

• First-in-human imaging test of the GRPR-targeted theranostic pair for advanced breast or prostate cancer

  This early feasibility study tests a GRPR-targeted imaging agent for PET and a low-dose radiopharmaceutical for SPECT in adults with advanced breast or prostate cancer to see if it is safe and can image tumors.

  Recruiting Early Phase 1 Integrated Haematology and Oncology Network · Perth, Western Australia · NCT07608848

• Morning versus evening timing of hormone therapy for metastatic breast and prostate cancer

  This pilot will test whether taking hormone-based cancer drugs in the morning or in the evening works better for people with metastatic breast or prostate cancer.

  Recruiting at 2 sites Phase 4 Ottawa Hospital Research Institute · Kitchener, Ontario and 2 other locations · NCT07252726

• Comparing methods to capture circulating tumor cells in metastatic breast or prostate cancer

  This one-day test will compare three blood-based methods (CellSearch®, Parsortix®, and SmartCatch®) to see which best finds circulating tumor cells in people with metastatic breast or prostate cancer before they start a new line of treatment.

  Recruiting Institut Claudius Regaud · Toulouse · NCT06904625

• Impact of Exercise and Statins on Cancer Treatment

  This study is testing if doing supervised exercise while taking cancer drugs helps people with metastatic breast, kidney, ovarian, and prostate cancer feel better and respond better to their treatment compared to exercising on their own, and if adding a cholesterol-lowering medication can make it even more effective.

  Recruiting Phase 3 Tampere University Hospital · Tampere, Länsi-Suomi · NCT05796973

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.